


## MART-1 Antibody [clone M2-7C10] (V2116)

Catalog No.	Formulation	Size
V2116-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V2116-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V2116SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V2116IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml


 Citations (7)

[Bulk quote request](#)


<b>Availability</b>	1-3 business days
<b>Species Reactivity</b>	Human
<b>Format</b>	Purified
<b>Host</b>	Mouse
<b>Clonality</b>	Monoclonal (mouse origin)
<b>Isotype</b>	Mouse IgG2b, lambda
<b>Clone Name</b>	M2-7C10
<b>Purity</b>	Protein G affinity chromatography
<b>Buffer</b>	1X PBS, pH 7.4
<b>Gene ID</b>	2315
<b>Localization</b>	Cytoplasmic
<b>Applications</b>	Western Blot : 2-4ug/ml Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT Prediluted IHC Only Format : incubate for 30 min at RT (1)
<b>Limitations</b>	This MART-1 Antibody Clone M2-7C10 is available for research use only.




MART-1 Antibody Clone M2-7C10 Melanoma Immunohistochemistry. IHC testing of FFPE human melanoma stained with MART-1 antibody (clone M2-7C10). Note cytoplasmic staining of cells. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min.




MART-1 Antibody Clone M2-7C10 Human Melanoma Tissue Immunohistochemistry. IHC testing of FFPE human melanoma stained with MART-1 antibody (clone M2-7C10). Note cytoplasmic staining of cells. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min.



MART-1 Antibody Clone M2-7C10 Human Skin Tissue Immunohistochemistry. IHC testing of FFPE human skin stained with MART-1 antibody (clone M2-7C10). Note cytoplasmic staining of cells. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min.



SDS-PAGE Analysis of Purified, BSA-Free MART-1 Antibody (clone M2-7C10). Confirmation of Integrity and Purity of the Antibody.



MART-1 Antibody Clone M2-7C10 WB. Western blot testing of human COLO-38 cell lysate with MART-1 antibody (clone M2-7C10). Expected molecular weight ~20 kDa.

## Description

MART-1 Antibody Clone M2-7C10 recognizes a protein doublet of 20-22kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. MART-1 is a melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. There are seven other melanoma associated antigens recognized by autologous cytotoxic T cells: MAGE-1, MAGE-3, tyrosinase, gp100, gp75, BAGE-1, and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum. This MART-1 antibody labels melanomas and other tumors showing melanocytic differentiation. It is also a useful positive-marker for angiomyolipomas. The antibody does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.

Explore our [Melan-A Antibody / Melanocyte Lineage Marker clone A103 page](#) for additional validation data and research applications involving melanoma biology, melanocytic tumor identification, and pigment cell differentiation pathways.

## Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the MART-1 Antibody Clone M2-7C10 to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

## Immunogen

Recombinant human MART-1 protein was used as the immunogen for this antibody.

## Storage

Store the MART-1 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

## Alternate Names

Antigen LB39-AA, Antigen SK29-AA, Melanoma antigen recognized by T-cells 1, MLAN-A antibody, MLANA antibody, MART-1 antibody, Melan-A antibody

## References (2)